Indeed, clinical studies have proven that low-dose IL-2 treatment in systemic lupus erythematosus (SLE) patients safely and effectively limits autoimmunity partially through direct inhibition of self-reactive TFH cells (41). Here, IL2 is linked to systemic lupus erythematosus.